Close Menu

Gustav Roussy

The multi-year collaboration will study a lung and breast cancer drug in adaptive Phase II trials, which will allow for the exploration of biomarkers of response and resistance.

A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.

Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.

With exome sequences from more than 600 metastatic breast tumors, researchers identified genomic alterations related to tumor progression, treatment response, and patient outcomes.

The firm hopes for a decision from the FDA later this year for its breast cancer drug candidate alpelisib, following results from a late-stage trial.